Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Withdrawal of Voxelotor: Implications for Clinical Practice in Sickl…

Akshat Jain

Managing Benign Hematology Disorders

Indy Hematology Review

C. Kessler

Understanding CRISPR and Gene Editing in the Treatment of Heme Malig…

UChicago Medicine

A. Cooper

How to Approach Anemia

Icahn School of Medicine at Mount Sinai

C. Cromwell

Highlights in Red Cell and Platelet Disorders From ASH 2023

Insights from 2023 ASH Annual Meeting

M. Blinder

ACP 2024 Insights: Sickle Cell Anemia - Diagnosis and Management of …

Insights from 2024 ACP Annual Meeting

M. Okam Achebe

Role of Antiplatelet and Anticoagulant Therapy: Managing Vaso-Occlus…

Erica Sparkenbaugh

Outcomes of Lovo-Cel Gene Therapy in Sickle Cell Disease: 60-Month F…

Yale Cancer Center

J. Ryu

Management of Hematologic Conditions in Athletes

Scripps Health

R. Kasthuri

Updates in Cellular Therapy for Sickle Cell Disease and Beta-Thalass…

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Peslak

Recent Gene Therapy Approvals in SCD: Clinical and Logistical Consid…

Nirmish Shah

A Guide for Shared Decision Making in Sickle Cell Disease

UCSF School of Medicine

M. Treadwell

Conference Highlights: Opioids in Medically Complex Patients - Old C…

2024 Conference Highlights

A. Mishkin

Exercises in CBC Interpretation: Sickle Cell Anemia

The Blood Project

N. Bavli

Gene Therapy for Sickle Cell Disease: Are We Where They Wanted Us to…

Cayenne Wellness 15th Annual Hybrid Sickle Cell Disease Educational Summit

A. Sharma

Managing the Benign Hematology Consult: Treatment Recommendations fo…

Indy Hematology Review

C. Kessler

Stroke and Transcranial Doppler in Congolese SCD

Leon Tshilolo

Sickle Cell Disease 101

Cayenne Wellness 15th Annual Hybrid Sickle Cell Disease Educational Summit

I. Osunkwo

ASH 2023 Summary: "Updates in Hereditary TTP and Sickle Cell Disease"

BMFcases

I. Ibrahim, T. Bat, Y. Shen